Their first collaborative effort in the hepatitis C virus space has spawned a promising Phase IIa-stage protease inhibitor, so Medivir AB and Tibotec BVBA are joining forces again in a potential €277 million (US$430 million) HCV deal aimed at developing polymerase inhibitors targeting NS5B. (BioWorld Today) Read More
